by Clinical Neuropsychologist Online | Wednesday, April 3, 2024 | Dementia
Abstract INTRODUCTION Aducanumab selectively targets aggregated forms of amyloid beta (Aβ), a neuropathological hallmark of Alzheimer’s disease (AD). METHODS PRIME was a Phase 1b, double-blind, randomized clinical trial of aducanumab. During the 12-month...
by Clinical Neuropsychologist Online | Tuesday, April 2, 2024 | Dementia
Abstract INTRODUCTION Genome-wide association studies have identified numerous disease susceptibility loci (DSLs) for Alzheimer’s disease (AD). However, only a limited number of studies have investigated the dependence of the genetic effect size of established...
by Clinical Neuropsychologist Online | Tuesday, April 2, 2024 | Dementia
Abstract INTRODUCTION We assessed whether macro- and/or micro-structural white matter properties are associated with cognitive resilience to Alzheimer’s disease pathology years prior to clinical onset. METHODS We examined whether global efficiency, an indicator...
by Clinical Neuropsychologist Online | Tuesday, April 2, 2024 | Dementia
Abstract INTRODUCTION We aimed to assess the effect of antidepressant use on dementia risk, cognitive decline, and brain atrophy. METHODS In this prospective cohort study, we included 5511 dementia-free participants (Mini-Mental State Examination [MMSE] > 25) of...
by Clinical Neuropsychologist Online | Tuesday, April 2, 2024 | Dementia
Abstract INTRODUCTION We conducted a rapid systematic review of minimal clinically important differences (MCIDs) for Alzheimer’s disease (AD) trial endpoints. METHODS Two reviewers searched EMBASE, MEDLINE, and PubMed from inception to June 4, 2023. RESULTS Ten...
by Clinical Neuropsychologist Online | Tuesday, April 2, 2024 | Dementia
Abstract INTRODUCTION There is limited knowledge about early-onset dementia (EOD) on fracture risk. METHODS Individuals ages 50 to 64 were identified from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (2012 to 2019). The...